Back to search

National and Kapodistrian University of Athens

Παρασκευή και αξιολόγηση φαρμακευτικών προϊόντων τροποποιημένης αποδέσμευσης για χορήγηση σε ανθρώπους και σκύλους

Abstract

dc:description

Part I:The aim of this investigation is to compare the release behavior of multiple-unit modified-release formulation (‘tablets in capsule’) of two active ingredients, mesalazine and theophylline, by the use of simple or enteric-coated capsules, with either dextran or pectin as excipients, with respect to powder filled capsules and the commercially available Asalazin® (500 mg mesalazine) and Theodur® (200 mg theopylline) in various pH media in the presence and absence of the enzyme Pectinex Ultra SP-L® solution, which degrades polysaccharides. The results indicate that dextran produces a thicker gelled layer than pectin and therefore, dextran based 'tablets in capsules' systems are suitable as a model extended release formulation. Capsules filled with powder mixture leads to different release profiles than 'tablets in capsule’ formulation. 3-Layered tablets release the drug at a slower rate in comparison to matrix tablets when pectin is used, but when dextran is used, the release profiles don't show significant difference. The product Pectinex Ultra SP-L® was found to affect the dissolution profiles when used as an additive to the media and, therefore, its use in the buffer solutions that mimick the large intestine/colon area during dissolution tests, especially when the formulations target this area, should be promoted.Part II:The knowledge of intraluminal dissolution in dogs is important in order to facilitate the development of pharmaceutical products for humans. The prediction of the dissolution in the GI tract of dogs would facilitate the provision of the product's behavior in human, taking into account the physiological differences between the two species, which today are significantly known. Also, the knowledge of the intraluminal dissolution in dogs is important to facilitate the development of pharmaceutical products for dogs. The interest in this field, at an international level is very high and important for the industry, the Food and Drug Administration (FDA) and some specialized research laboratories.During testing the use of the dissolution paddle apparatus and the continuous dissolution flow system, as described in pharmacopoeias, in predicting theophylline release from modified release products in the GI tract of healthy adults during fasted state, it is observed that the dissolution paddle apparatus and Level 0 simulation media data initially comply but later on underestimate the release of theophylline. The results when using the continuous flow system and Level I simulation media underestimate the release of theophylline.During the study of theophylline release from Theodur® 200 mg in dog and in human in fasted state and the prediction from in vitro experiments, it appears that, although the number of dogs used in this study was small (n = 3), the intraluminal dissolution is more complete in dogs compared to humans. Moreover, it seems that the slightly reduced release in humans, is in agreement with the reduced release in vitro.Media (Level I and II) that simulate the environment in the stomach (FaSSGFc pH 1,5 and pH 6,5) and in the upper small intestine (FaSSIFc) of the dog in fasted state have been previously proposed (Arndt et al., 2013). In this study, media that simulate the environment of the large intestine (FaSSCoFc, Level I) and experimental times for monolithic pharmaceutical modified release products in canine fasted state are proposed. Further, media (Level I and II) that simulate the physicochemical characteristics in the gastrointestinal tract of dogs during fed state (FeSSGFc, FeSSIFc, FeSSIFileum, c, and FeSSCoFc) and duration of experimentation in the in vitro dissolution / release assays are proposed.During the evaluation of the dissolution paddle apparatus in predicting the intraluminal dissolution of modified release of monolithic products in dogs in fasted state, it is observed that in the case of Theo-dur® 200 mg tablet, the in vitro experiment data in both simulation media Levels I and II managed to predict the in vivo data for the two hours after administration. Afterwards, it seems that the results underestimate the intraluminal procedure and additional data is needed. In the case of ER-5T 200 mg tablet the in vitro data underestimate the in vivo experimental data. The underestimation of the process of intraluminal dissolution in dogs may be due to the fact that the stirring intensity is not sufficient as the motility in the gastrointestinal lumen of dogs is increased in relation to that of humans.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2017

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Siamidi, Angeliki
  • Σιαμίδη, Αγγελική-Παναγιώτα

Subjects

dc:subject × 10

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/40959

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Siamidi, Angeliki; Σιαμίδη, Αγγελική-Παναγιώτα. Παρασκευή και αξιολόγηση φαρμακευτικών προϊόντων τροποποιημένης αποδέσμευσης για χορήγηση σε ανθρώπους και σκύλους. National and Kapodistrian University of Athens, 2017. http://hdl.handle.net/10442/hedi/40959